The Declare-Timi trial’s success was driven by a decrease in cardiovascular hospitalisations rather than deaths, but Astra put this down to the lower-risk population…
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Split congressional control will result in more drug pricing talk, but don’t expect much action.
The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
Crunch time nears for oral semaglutide and Novo will find out if concizumab can cut it in a crowded haemophilia market.
Pfizer and Lilly appear to have sacrificed some efficacy for safety with their anti-NGF pain project, tanezumab.
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
As a crucial test of the cytokine approach nears from Nektar, encouraging early data from Lilly and Roche confirm that the competition is hotting up.
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.